Skyepharma shares up despite falling into the red
Shares in SkyePharma rose despite the drug development firm reporting a fall in revenue and a plunge into the red for the year ended December 31st.
Shares in SkyePharma rose despite the drug development firm reporting a fall in revenue and a plunge into the red for the year ended December 31st.
The firm recorded a pre-tax loss of £1.6m in 2011, down from a profit of £6.3m the year before, on revenues which fell from £58.1m to £55.2m.
Peter Grant, Chief Executive Officer, said: "The group made significant progress on the delivery of its strategy during 2011. As anticipated, revenues and operating profits were lower than 2010, due to substantial non-recurring revenues in 2010, but profitability remained in line with the board's expectations.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
"This year will be pivotal for SkyePharma - our key goals are to obtain the marketing authorisation and launch of Flutiform in Europe, potential filing of Flutiform in Japan and reach agreements to reorganise the group's finances to align repayment obligations with the group's cash generative potential."
Revenues for the current year are set to benefit from milestones of €8m (£6.7m) if Flutiform is approved and launched in initial markets in Europe.
Contract research and development revenues are forecast to show some growth compared with 2011.
The board said it expects that liquidity will benefit from a $10m (£6.5m) milestone payment due when Pacira achieves the first commercial sale of EXPAREL in the United States. This is anticipated in the second quarter of 2012.
Cash at the end of the period fell from £29m to £15.2m.
The share price rose 2.44% to 42.00p by 11:46.
NR
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
MoneyWeek is written by a team of experienced and award-winning journalists, plus expert columnists. As well as daily digital news and features, MoneyWeek also publishes a weekly magazine, covering investing and personal finance. From share tips, pensions, gold to practical investment tips - we provide a round-up to help you make money and keep it.
-
‘Inheritance tax insurance’ enquiries are soaring – but is it worth it?
Premiums for whole of life insurance can run to £5,000 a month to cover a £300,000 inheritance tax bill, with policies costing more the older you take them out.
-
MPs warn over Lifetime ISAs which could leave savers out of pocket
The Treasury Committee has highlighted confusion around the Lifetime ISA withdrawal charge, which risks consumers losing “a significant part of their savings”